Ceramisys is located in Sheffield, UK and is leading international biomaterials manufacturer with a strong focus on orthopedic and dental applications. ReproBone® bone graft  substitutes are manufactured in granular and paste forms. The chemical composition of their matrices is very similar to that found in human cancellous bone and acts as an ideal scaffold for bone support and regeneration.

Ceramisys's have expertise in the manufacture, development and  commercialisation of bone graft substitutes.  Ceramisys's role in the IMCOSS project is to coordinate and manage the consortium whilst carrying out research on the the materials and devices developed as part of this project.

Fluidinova is a specialized manufacturer of synthetic nanocrystalline hydroxyapatite material, which is commercialized under the brand name nanoXIM. Using an innovative proprietary technology – NETmix – Fluidinova produces a highly pure, single phase nanoHydroxyapatite.nanoXIM is supplied worldwide in different forms to manufacture Medical Devices, for Personal Care Product formulations, R&D activities and many other applications.

Fluidinova’s role in the IMCOSS project is to develop, manufacture and provide nano sized Calcium Phosphate materials to incorporate in the products to be developed and tested within the project.

Primequal™ is a Swiss Company specializing in prefilled syringes (pfs) and injection devices for pharmaceutical drug delivery. Based on an innovative patented “1 Click 1 Dose™” technology, Preciquant™ is an automatic Dispenser - Doser - Injector that is able to propel a liquid, cream, gel or paste. Equipped with a single button, it enables a safer, faster, precise and repeated dose delivery. For the first time, a step-by-step doser is available in a single use – disposable elegant device. It is designed to provide greater patient comfort in a safer and faster treatment with consistent outcomes and higher patient satisfaction. The Preciquant™ technology has received the coveted Pharmapack Innovation Award 2011 for its “ease of use”. 

For the IMCOSS project, Primequal mission is to develop a specific delivery system that complies with the unusual specification of a nanotech bone grafting product, its handling and its compliance with the latest regulatory issues on human factors to guarantee the success of the treatment.


The University of Sheffield is a research led and internationally competitive university.

The School of Clinical Dentistry at Sheffield ranks as one of the top Schools in the UK. In the RAE 2008, 70% of our work was graded as world leading or internationally excellent and we were ranked fourth among UK Dental Schools. The School achieved an “excellent” (23/24) rating in the last (2001) QAA Subject Review exercise, and in a recent independent review of teaching was described as ‘an excellent school of international calibre’.

The School and the Charles Clifford Dental Hospital have recently completed a £14.5 million redevelopment and has an intake of 79 dental undergraduates for its five year BDS programme, an annual intake of 30 students on the Diploma in Dental Hygiene and Dental Therapy course, and a significant annual intake of postgraduate students on taught courses and reading for higher degrees by research.

The project is run in collaboration with the Department of Materials, Science and Engineering, one of the largest and most influential materials departments in the country. The department works with industry partners locally and globally to solve problems and improve our world and produces groundbreaking research covering all aspects of materials – from magnetics and metals to tissue engineering and nanotechnology.


The primary objective of the Center for Traumatology Research is to improve diagnostic and therapeutic measures in  trauma care specifically in the area of intensive care and tissue regeneration. Interdisciplinary cooperation allows the center to be engaged in many fields of medicine, stemming not only from diverse research projects, but also analysis of international research results and their practical application within the AUVA (clinical studies and Continuing Education).

© 2012 IMCOSS Consortium